Difficulties of diagnosis and characteristics of clinical progression of anaplastic thyroid cancer. Clinical case
https://doi.org/10.17650/2782-3202-2022-2-4-22-26
Abstract
The article describes clinical observation of locally advanced metastatic anaplastic thyroid cancer. Difficulties in instrumental and laboratory diagnosis of this pathology and the role of molecular diagnosis in search for highly effective treatment are discussed.
About the Authors
A. M. Mudunov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081; Bld. 2, 8 Trubetskaya St., Moscow 119991
B. G. Pkheshkhova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; RUDN University
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081; 6 Miklukho-Maklaya St., Moscow 117198
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081; Bld. 2, 8 Trubetskaya St., Moscow 119991
A. A. Fedenko
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. F. Batsev
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
M. B. Pak
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
Maksim B. Pak.
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081; Bld. 2, 8 Trubetskaya St., Moscow 119991
References
1. Ragazzi M., Ciarrocchi A., Sancisi V. et al. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol 2014;2014:790834. DOI: 10.1155/2014/790834
2. De Lellis R.A., Lloyd R.V. , Heitz P.U., Eng C. Pathology and genetics of tumors of endocrine organs. IARC, Lyon, France, 2004.
3. Untch B.R., Olson J.A. Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15(3):661-79. DOI: 10.1016/j.soc.2006.05.006
4. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7(10):569-80. DOI: 10.1038/nrendo.2011.142
5. Smallridge R.C., Ain K.B., Asa S.L. et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22(11):1104-39. DOI: 10.1089/thy.2012.0302
6. Sherman S.I. Anaplastic carcinoma: clinical aspects. In: Thyroid cancer: a comprehensive guide to clinical management. Ed. by L. Wartofsky, D. Van Nostrand. 2nd edn. Totowa: Humana Press, 2006. Pp. 629-632.
7. Asa S.L., Bedard Y.C. Fine-needle aspiration cytology and histopathology. In: Thyroid cancer: diagnosis and treatment. Ed. by O.H. Clark, S. Noguchi. St. Louis: Quality Medical Publishing, 2000. Pp. 105-126.
8. Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13(4):453-64. DOI: 10.1245/ASO.2006.05.042
9. McIver B., Hay I.D., Giuffrida D.F. et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130(6):1028-34. DOI: 10.1067/msy.2001.118266
10. De Crevoisier R., Baudin E., Bachelot A. et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60(4):1137-43. DOI: 10.1016/j.ijrobp.2004.05.032
11. Mohebati A., Dilorenzo M., Palmer F. et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol 2014;21(5):1665-70. DOI: 10.1245/s10434-014-3545-5
12. Keutgen X.M., Sadowski S.M., Kebebew E. Management of anaplastic thyroid cancer. Gland Surg 2015;4(1):44-51. DOI: 10.3978/j.issn.2227-684X.2014.12.02
13. Paraiso K.H., Fedorenko I.V., Cantini L.P. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102(12):1724-30. DOI: 10.1038/sj.bjc.6605714
14. Flaherty K.T., Infante J.R., Daud A. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694-703. DOI: 10.1056/NEJMoa1210093
15. U.S. Food and Drug Administration. FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-anaplastic-thyroid-cancer-braf-v600e-mutation
16. Capdevila J., Wirth L.J., Ernst T. et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 2020;38(23):2620-7. DOI: 10.1200/JCO.19.02727
17. Bastman J.J., Serracino H.S., Zhu Y. et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2016;101(7):2863-73. DOI: 10.1210/jc.2015-4227.
Review
For citations:
Mudunov A.M., Pkheshkhova B.G., Zeynalova P.A., Fedenko A.A., Batsev A.F., Pak M.B. Difficulties of diagnosis and characteristics of clinical progression of anaplastic thyroid cancer. Clinical case. MD-Onco. 2022;2(4):22-26. (In Russ.) https://doi.org/10.17650/2782-3202-2022-2-4-22-26
Views:
266
Email this article 